Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

Brigatinib demonstrated clinically meaningful systemic and intracranial efficacy in patients with ALK TKI-naive ALK+ NSCLC. Safety results were consistent with the known profile for brigatinib.

Authors

Institutions

Publication Details

Journal
Lung Cancer
Published
2025-02-04
DOI
https://doi.org/10.1016/j.lungcan.2025.108424
Citations
3
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
4.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

Ki Hyeong Lee, Maximilian J. Hochmair, Masashi Kondo, Ji‐Youn Han et al.
3 citations
Lung Cancer
Lung Cancer Treatments and Mutations
4.56
article

Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

Ki Hyeong Lee, Maximilian J. Hochmair, Masashi Kondo, Ji‐Youn Han, Myung‐Ju Ahn, Takayuki Asato, Robert J. Fram, Sanjay Popat, Yuichiro Ohe, James Chih‐Hsin Yang, Angelo Delmonte, Kentarou Kudou, Florin Vranceanu, Shunichi Sugawara, Bradley Hupf, D. Ross Camidge, Hye Ryun Kim
article en
3 citations

Abstract

Brigatinib demonstrated clinically meaningful systemic and intracranial efficacy in patients with ALK TKI-naive ALK+ NSCLC. Safety results were consistent with the known profile for brigatinib.

Lung CancerVol. 201
Fujita Health University (JP), Yonsei University (KR), Samsung Medical Center (KR), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), National Cancer Center (KR), Royal Marsden Hospital (GB), National Taiwan University Hospital (TW), University of Colorado Cancer Center (US), Takeda (United States) (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Chungbuk National University Hospital (KR), Karl Landsteiner Society (AT), Sendai Kousei Hospital (JP), Takeda (Japan) (JP), Sungkyunkwan University (KR), University of Colorado Denver (US)
Takeda Oncology
Openalex Percentile: Top 7%
Lung Cancer Treatments and Mutations
4.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.